Replies to post #94208 on Biotech Values

[go seek]

IDIX - apparently "someone" loves the IDX184 news...
up $1.02 on heavy volume in the premarket. Wow!

[mcbio]

IDIX exit strategy

IDX184 addendum: These data ought to be good enough for IDIX to ink a nice partnership deal—either for IDX184 alone or for a package of IDX184 and one or more of IDIX’s other HCV drug candidates.

Dew, any comments on your exit strategy for your IDIX holdings? I'm sure this depends to a large degree on newsflow and corresponding valuation, which is unpredictable. But, based on news to date and current valuation, any comments? Do you have a specific share price in mind or are you just waiting for specific newsflow (e.g. partnership for IDX184) or are you just focused on holding for a certain number of years to allow for more newsflow?

My thoughts are that, absent any additional positive newsflow, I don't plan to sell any shares below $6/share. I'd be happy and would probably sell all my holdings if the stock got to $8, but I'm sure it would take pretty material newsflow for the stock to reach that level (company buyout or very lucrative deal for IDX184 possibly). Obviously, material negative newsflow can change one's exit strategy but I hope to not have to cross that bridge.